Baili Tianheng: Innovative Drug BL-ARC002 Approved for Clinical Trials

LightningPacketLoss · 2026-03-23T08:55:32+00:00

Bai Li Tianheng recently announced that its innovative drug BL-ARC002 injection has been approved by the National Medical Products Administration for clinical trials targeting advanced solid tumors. The drug is a globally first-in-class antibody-radionuclide conjugate with high targeting specificity and tumor enrichment, and is expected to overcome drug resistance issues.

LightningPacketLoss

2026-03-23 08:55:32

Abstract generation in progress

Recently, Baili Tianheng announced that the company has received the official “Drug Clinical Trial Approval Notice” from the National Medical Products Administration. The company’s self-developed innovative drug, BL-ARC002 injection, has been approved for clinical trials. This drug is mainly used for the treatment of advanced solid tumors. Applicants include Chengdu Baili Dote Biopharmaceutical Co., Ltd. and Sichuan Baili Pharmaceutical Co., Ltd.

BL-ARC002 is the company’s Class I innovative drug in the field of antibody-radioisotope conjugates (ARC), with fully independent intellectual property rights. It is expected to be the world’s first ARC drug. The drug utilizes antibody-mediated precise targeted delivery technology, offering stronger target specificity and higher tumor accumulation, and is expected to demonstrate better efficacy against drug resistance.

(Baili Tianheng Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.